Eledon Pharmaceuticals reported progress in its tegoprubart clinical programs, including plans to start a global Phase 3 trial in kidney transplantation by Q4 2026. The FDA granted Fast Track designation for tegoprubart to prevent kidney transplant rejection and cleared an IND for a study in islet cell transplantation for type 1 diabetes. New data showed improved patient outcomes versus standard therapy. Financially, Eledon ended Q3 2026 with $69.7 million in cash and investments, supporting operations into Q2 2027. Upcoming milestones include initiating multiple clinical trials and receiving FDA guidance on kidney xenotransplantation.
Eledon Pharmaceuticals' recent financial and clinical updates provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 23 rose and 124 fell today. Notable movers include RXRX at USD 3.34 with a -6.96% change and a typical hold time of 23 days, HRTX at USD 0.33 down 6.90% with a 39-day hold, and TWST at USD 114.14 down 6.89% with a 27-day hold. Pluang order activity varied, with TWST showing 76% sell orders.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
